Drug-Target Information
Drug Name Target Name Drug Type Target Type Source Drug MeSHID Interaction Score Drug Status Target Action
ficlatuzumab hepatocyte growth factor NA Clinical trial target TTD , DGIDB Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Multiple Myeloma[MeSHID:D009101]
Malignant neoplasm of pancreas[MeSHID:D010190]
Leukemia
Myelocytic
Acute[MeSHID:D015470]
Pancreatic carcinoma[MeSHID:C562463]
Non-Small Cell Lung Carcinoma[MeSHID:D002289]
Squamous cell carcinoma[MeSHID:D002294]		 13.26 phase 2 antibody
ficlatuzumab hepatocyte growth factor NA Clinical trial target TTD , DGIDB Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Multiple Myeloma[MeSHID:D009101]
Malignant neoplasm of pancreas[MeSHID:D010190]
Leukemia
Myelocytic
Acute[MeSHID:D015470]
Pancreatic carcinoma[MeSHID:C562463]
Non-Small Cell Lung Carcinoma[MeSHID:D002289]
Squamous cell carcinoma[MeSHID:D002294]		 13.26 phase 2 unknown
ficlatuzumab hepatocyte growth factor NA Clinical trial target TTD , DGIDB Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Multiple Myeloma[MeSHID:D009101]
Malignant neoplasm of pancreas[MeSHID:D010190]
Leukemia
Myelocytic
Acute[MeSHID:D015470]
Pancreatic carcinoma[MeSHID:C562463]
Non-Small Cell Lung Carcinoma[MeSHID:D002289]
Squamous cell carcinoma[MeSHID:D002294]		 13.26 phase 2 inhibitor
click here to return to the previous page